New method of delivering chemotherapy using ultrasound works in BYU lab

December 19, 2002

PROVO, Utah - Cancer patients undergoing chemotherapy often endure painful side effects caused by the powerful drugs as they course through their entire bodies, damaging healthy tissue and tumors alike.

Brigham Young University researchers are reporting in the December issue of the prestigious oncology journal "Cancer Research" that they have successfully tested a new method in laboratory animals that would concentrate the impact of cancer drugs on specific cancerous tissues, thus sparing the rest of the body from harm.

Their method combines two, key innovations: packaging a drug in tiny molecules of water-soluble plastic so that the drug would not interact while passing through a person's bloodstream, then using ultrasound to release the drug from its package at the specific part of the body affected by the cancer.

William G. Pitt, professor of chemical engineering at BYU and principal investigator on the project, said he is pleased that the tests produced significant reductions of tumor size in laboratory animals.

"This method shows potential in offering controlled drug delivery, which could reduce the negative side effects that arise during chemotherapy and could localize the treatment at the tumor site," said Pitt, cautioning that human application is still several years away.

Richard H. Wheeler, director of clinical research for the Huntsman Cancer Institute, says Pitt's research is interesting and innovative.

"The use of focused ultrasound to release the packaged drug maximally within tumor tissue holds promise for the cancer patient of increasing the chance for tumor response while reducing side effects," said Wheeler.

The experiments are the product of years of work on ultrasound drug delivery by Pitt combined with that of Natalya Rapoport, a professor of bioengineering at the University of Utah, who has been studying the physics and chemistry of drug delivery using water-soluble plastics called micelles. Made of polyethylene oxide and polypropylene oxide, micelles are a self-assembled collection of molecules that spontaneously form tiny plastic spheres when introduced into water.

In previous work, Pitt and Rapoport found that an anti-cancer drug called doxorubicin is averse to water and seeks "protection" inside the micelles when both are mixed in water. They hypothesized that the drug, safely encapsulated in microscopic micelle "vehicles," could be injected into a cancer patient and travel through the bloodstream without any side effects. At an appointed time, a physician could apply ultrasound to a tumor and release the drug to that tumor site only.

After successful trials in test tubes, Pitt had a graduate student, Jared Nelson, inject doxorubicin contained within the plastic micelle carrier and apply various levels of ultrasound to cancer tumors placed in rats' legs. The size of the tumor was measured and observed over the four-week treatment period. At the experiment's conclusion, Pitt and Nelson found that the application of the drug in combination with ultrasound significantly reduced the tumor size when compared to tumors that were not exposed to ultrasound.

"We believe that ultrasound releases the DOX from the micelles and that it could also be assisting the drug to enter the tumor cells," said Nelson, who became an associate scientist for pharmaceutical company Pfizer after completing the study and graduating in April.

"This research shows that ultrasound can be used to selectively release one kind of anti-cancer drug at a tumor site and reduce the size of that tumor in a rat model," said Pitt.

"We are excited about the findings, but still need to optimize the process before we take it to the next step."

If further experiments prove successful, the method would be tested on other animals using different kinds of drugs and ultrasound frequencies before trials on humans could begin, a prospect that is still several years away.

Beverly Roeder, a veterinarian and BYU professor of integrative biology, helped develop the procedure to do this study on tumors in rats. John Carmen, a master's student in microbiology and Friederike Roloff, an undergraduate in microbiology at the time of the study, helped with the study and co-authored the "Cancer Research" article that appears in the Dec.15 issue. Their study was funded by the BYU Cancer Research Center. Further funding from the National Institutes of Health via a grant to Rapoport at the University of Utah will enable Pitt's laboratory to continue research in this area.

Brigham Young University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to